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Abstract
Background: Brain metastases (BM) from hepatocellular carcinoma (HCC) are extremely rare and are associated
with a poor prognosis. The aim of this study was to define clinical outcome and prognostic determinants in
patients with BM from HCC.
Methods: Between January 1994 and December 2009, all patients with HCC and BM treated in Sun Yat-sen
University Cancer Center were retrospectively reviewed. Univariate and multivariate survival analyses were
performed to identify possible prognostic factors.
Results: Forty-one patients were diagnosed with BM from HCC, an incidence of 0.47%. The median age at
diagnosis of BM was 48.5 years. Thirty-three patients (80.5%) developed extracranial metastases at diagnosis of BM,
and 30 patients (73.2%) had hepatitis B. Intracranial hemorrhage occurred in 19 patients (46.3%). BM were treated
primarily either with whole brain radiation therapy (WBRT; 5 patients), stereotactic radiosurgery (SRS; 7 patients), or
surgical resection (6 patients). The cause of death was systemic disease in 17 patients and neurological disease in
23. Patients in a high RPA (recursive partitioning analysis) class, treated with conservatively and without lung
metastases, tended to die from neurological disease. Median survival after the diagnosis of BM was 3 months (95%
confidence interval: 2.2-3.8 months). In multivariate analysis, the presence of extracranial metastases, a low RPA
class and aggressive treatment, were positively associated with improved survival.
Conclusions: BM from HCC is rare and associated with an extremely poor prognosis. However, patients with a low
RPA class may benefit from aggressive treatment. The clinical implication of extracranial metastases in HCC patients
with BM needs further assessment.
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Background
Hepatocellular carcinoma (HCC) represents one of the
most common causes of cancer related deaths world-
wide [1]. The incidence of HCC demonstrates a striking
geographic variability, with the highest rates in East and
South-East Asia and Sub-Saharan Africa [1]. It is also
one of the top three causes of cancer death in the Asia
Pacific region, as a result of the high prevalence of the
main etiological agents, hepatitis B virus and C virus
infections [2]. In the United States and Europe, where
chronic hepatitis C virus infections have been rising, the
incidence of HCC is expected to increase further in the
next two to three decades [3]. China is an area with epi-
demic hepatitis B virus, and is estimated to account for
half of HCC related deaths worldwide [4].
The presence of brain metastases (BM) is associated
with significant morbidity and mortality, and consider-
able research has focused on improving both survival and
quality of life for these patients. BM are most frequently
diagnosed in patients with lung, breast and melanoma
primaries [5]. However, BM from HCC is extremely rare,
with a reported frequency ranging from 0.2% to 2.2% at
autopsy [6-9]. Recent therapeutic advances in surgical
techniques, including transarterial chemoemobolization
(TACE), local ablation, and chemotherapeutic agents,
have all contributed to improved survival rates [3]. As a
result, the incidence of BM is expected to increase as a
result of longer survival for some patients [8]. However,
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with a median survival of only 1-2 months [7,10,11].
Furthermore, due to its rarity, the identification of prog-
nostic factors and optimal treatment strategies are still
being researched. To date, only a few studies from Asia
and a small series from America and Europe have been
reported [7,8,10-15]. Similar studies from China are lack-
ing. Therefore, in the present study we retrospectively
reviewed those patients treated in Sun Yat-sen University
Cancer Center (SYSUCC) in China, in an attempt to
explore both the clinical characteristics and potential
prognostic factors associated with survival in patients
with HCC and BM.
Methods
Patient population
All patients treated in SYSUCC were prospectively
enrolled into a database. Using this database, we identified
10,788 patients diagnosed with HCC between January
1994 and December 2009. Of 8,676 patients with complete
follow-up data, 41 developed BM with an incidence of
0.47%, and 7166 patients were detected with hepatitis B
virus infection (82.6%), 208 patients with hepatitis C virus
infection (2.4%). Diagnosis of HCC was histologically con-
firmed by surgical resection or by biopsy of the liver mass.
The diagnosis in patients without tissue proof was con-
firmed using the radiological criteria of the presence of a
hepatic mass greater than 2 cm identified on one dynamic
imaging technique with a typical vascular pattern [3]. The
diagnosis of BM from HCC was confirmed by computer-
ized tomography (CT) and/or magnetic resonance imaging
(MRI), with or without pathological evidence. Six patients
were excluded where the diagnosis was based solely on
clinical suspicion, which was not confirmed with imaging
evidence. The follow-up period was terminated by death
or by the end of the study itself (December 2010). All
patients were known to have died at the final follow-up.
Data collection
All clinical information was retrieved from archived files
with the approval of the institutional review board of
SYSUCC. Clinical data, including patient demography,
clinical presentation, Child-Pugh classification, treatment
modality and survival time, was collected. Levels of
alpha-fetoprotein (AFP), carcinoembryonic antigen
(CEA) and carbohydrate antigen 19-9 (CA19-9) were also
reviewed. Patients were assigned to a Radiation Therapy
Oncology Group (RTOG) recursive partitioning analysis
(RPA) classification following the diagnosis of BM. Four
criteria were applied in order to stratify patients: Kar-
nofsky performance status (KPS), primary tumor status,
age, and the presence of extracranial metastases. Patients
in RPA class I had a KPS ≥ 70, were aged < 65 years, the
primary tumor was controlled, and there was no evidence
of extracranial metastases. Patients in RPA class III had a
KPS < 70. The rest of the patients were in RPA class II
[16]. A controlled primary tumor refers to a primary
tumor in complete remission after surgical resection or
local therapy [7]. The cause of death was determined
using the protocol as described by Patchell et al. [17].
Statistical analysis
Overall survival (OS) was calculated from the radio-
graphic diagnosis of BM until death, or until the date of
last follow-up visit for patients who were still alive. Man-
tel-Cox log-rank test stratified for each factor was applied
to compare the Kaplan-Meier curves for survival. Cox
proportional hazard model analysis was performed to
identify the prognostic factors for OS. Variables with a
P < 0.05 in univariate analysis were included in the multi-
variate survival analysis. Analyses were performed using
SPSS software 16.0 (SPSS, Chicago, IL, US). A P-value
less than 0.05 was considered statistically significant.
Results
Patient population
A total of 41 patients were diagnosed with BM from HCC,
comprising 33 males and 8 females. The median age at
diagnosis of HCC was 46.5 years (range, 24.5-81 years).
Hepatitis B virus infection was detected in 30 patients
(73.2%), and no patient was infected by hepatitis C virus.
The majority of patients had undergone surgical resection,
laser ablation and/or TACE to treat the primary HCC.
Additionally, 2 patients received oral sorafenib for 3
months following a diagnosis of lung metastases. Neither,
however, showed a response in terms of tumor control. At
the diagnosis of BM, the primary HCC was controlled in
16 patients (39%). Additional demographic data relating to
the primary tumor is shown in Table 1.
The median age at diagnosis of BM was 48.5 years
(range, 25-82 years). The median interval between diagno-
sis of HCC and diagnosis of BM was 15 months (range, 0-
120 months). Most patients (80.5%) had already developed
extracranial metastases at the diagnosis of BM. Lung
metastases were the most frequent (75.6%), followed by
bone (22%) and adrenal gland (9.8%). Twenty-four patients
(58.5%) presented with a single brain metastasis, and
70.7% of brain lesions were supratentorial. The most fre-
quent presenting symptoms were headache, nausea, and
motor weakness. Only one patient was asymptomatic, and
the diagnosis was made using whole body positron emis-
sion computed tomography (PET-CT). Intracranial
hemorrhage occurred in 19 patients (46.3%). Patient char-
acteristics are summarized in Table 2.
Treatment
Symptomatic patients with surrounding brain edema
generally received intravenous dexamethasone following
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Page 2 of 9the diagnosis of BM. Aggressive treatment included sur-
gical resection, stereotacticr a d i o s u r g e r y( S R S ) ,w h o l e
brain radiosurgery (WBRT), and systemic chemotherapy.
Treatment modalities were diverse and were based on
many factors, including the overall general condition of
the patient, the extent of the disease, the number and
location of brain lesions, as well as issues relating to the
discretion of the individual physician and patients’ per-
sonal preferences. For those in a relatively poor condi-
tion and/or refusing aggressive treatment, supportive
treatment was undertaken. Treatment modalities for this
group are shown in detail in Table 3.
Six patients accepted surgical resection, and complete
resection was achieved in four. In two patients in whom
the tumor recurred, SRS plus WBRT was performed for
one patient, and SRS alone for the other. Two patients
received subtotal resection followed by adjuvant SRS.
Five patients underwent WBRT alone. The most fre-
quently used fractionation schedule was 30 Gy in 10 frac-
tions (dose range 22.5-30 Gy; mean 28.5 Gy, SD = 3.5
Gy). Seven patients received SRS alone, the median maxi-
mal and marginal doses of SRS were 34 Gy (range, 30-38
Gy) and 16 Gy (range, 14-20 Gy)..
Outcome and prognostic analysis
At the final follow-up, all patients had died. Of the 40
patients with a documented cause of death, 23 patients
(57.5%) died from the progression of BMs and 17
Table 1 Characteristics of hepatocellular carcinoma
(n = 41)
Characteristic No.(%)
Median age at diagnosis of HCC (range), years 46.5(24.5-81)
Etiology
Hepatitis B 30(73.2%)
Without hepatitis 11(26.8%)
Treatment
Hepatic resection 22(53.7%)
TACE 27(65.9%)
Chemotherapy 6(14.6%)
Radiotherapy 3(7.3%)
Ablation 3(7.3%)
Hepatic transplantation 2(4.9%)
None 3(7.3%)
Primary tumor
Controlled 16(39%)
Uncontrolled 25(61%)
Child-Pugh’s classification
A 27(65.9%)
B 8(19.5%)
C 6(14.6%)
Table 2 Characteristics of brain metastasis (n = 41)
Characteristic No.(%)
Median age at diagnosis of HCC (range), years 48.5(25-82)
Median interval between diagnosis of BM from HCC
(range), months
15(0-120)
Age at diagnosis of HCC (years)
< 50 23(56.1%)
≥ 50 18(43.9%)
Gender
Female 8(19.5%)
Male 33(80.5%)
Site of extracranial metastases
Lung 31(75.6%)
Bone 9(22%)
Adrenal gland 4(9.8%)
other sites 3(7.3%)
Radiological data
CT 22(53.7%)
MRI 19(46.3%)
Location of brain lesions
Supratentorial 29(70.7%)
Infratentorial 7(17.1%)
Combinations 5(12.2%)
APF (ng/ml)
< 400 15(36.6%)
≥ 400 26(63.4%)
CEA (ng/ml)
< 5 26(63.4%)
≥ 5 5(12.2%)
Unkown 10(24.4%)
CA199 (u/ml)
< 35 22(53.7%)
≥ 35 10(24.4%)
Unkown 9(22%)
Symptom
Headache 17(41.5%)
Motor weakness 14(34.1%)
Nausea 12(29.3%)
Mental change 6(14.6%)
Seizure 4(9.8%)
Visual disturbance 4(9.8%)
Cerebellar dysfunction 3(7.3%)
Aphasia 2(4.9%)
None 1(2.4%)
Interval between diagnosis of HCC and BM (months)
< 12 25(61%)
≥ 12 16(39%)
Number of brain lesions
1 24(58.5%)
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ease. The impact of patient characteristics and treatment
modality on the cause of death was assessed (Table 4).
Patients in RPA class III or treated conservatively mainly
died as a result of progression of BM. In addition, it was
observed that patients with lung metastases were more
likely to die from progression of systemic lesions.
The median overall survival time (MST) after diagnosis
of BM was 3 months (95% confidence interval: 2.2-3.8
months) (Figure 1a). The 1 month, 6 month and 12
month survival rates were 87.8%, 31.7% and 7.3%, respec-
tively. Tables 5 and 6 demonstrate the results of univari-
ate and multivariate survival analysis, respectively.
The MST of patients with RPA class I or II was signif-
icantly longer than that of RPA class III (6 vs. 1 month,
P < 0.0001) (Figure 1b). In the multivariate analysis, the
RPA class was revealed as the strongest prognostic fac-
tor. Patients with extracranial metastasis before or
alongside the diagnosis of BM had a longer survival
than those without extracranial metastasis (3.5 months
vs. 1 month, P < 0.0001) (Figure 1c). This relationship
remained true in multivariate analysis.
Additionally, patients with lung metastases at the time
of diagnosis of BM had a longer survival time compared
to those without lung metastasis, although this relation-
ship was no longer significant in the multivariate model.
However, there was no survival difference according to
gender, age, control of HCC, liver function, levels of
AFP, CEA and CA19-9, hepatitis virus B infection, intra-
cranial hemorrhage, location and number of brain
lesions, and interval between diagnosis of HCC and BM,
in our patient group.
The impact of the treatment modality on overall survival
was also evaluated in univariate and multivariate analyses.
Aggressive treatment was shown to be associated with a
longer survival in univariate analysis (4.5 vs. 1.5 months,
P = 0.001), which remained an independent prognostic
factor in the multivariate model (Figure 2).
Discussion
With longer survival of patients and enhanced imaging
detection techniques, the reported incidence of extra-
hepatic metastases in patients with HCC patients is
increasing [18]. The most common site for metastases is
the lung, followed by regional lymph nodes, bone, the
adrenal gland, and occasionally the peritoneum, pancreas,
and kidney [18,19]. BM fromH C Ci sal e s sc o m m o n
occurrence, with various incidence rates reported in the
literature. A small series from Korea and Japan reported
an incidence of brain metastases between 0.05 and 2.2%
[6,8,9,11,20]. The most recent literature from Korea com-
piled the largest cohort to date, with 62 cases of BM
Table 2 Characteristics of brain metastasis (n = 41)
(Continued)
2 4(9.8%)
≥ 3 13(31.7%)
Brain hemorrhage
Yes 19(46.3%)
No 22(53.7%)
KPS
90-100 6(14.6%)
80-89 7(17.1%)
70-79 12(29.3%)
60-69 9(22%)
< 60 7(17.1%)
RPA class
I 1(2.4%)
II 24(58.5%)
III 16(39.0%)
Table 3 Treatment modality for the patients (n = 41)
Treatment No.(%)
Conservative treatment 23(56.1%)
Aggressive treatment 18(43.9%)
Surgical resection alone 4(9.8%)
Surgery ® SRS 2(4.9%)
SRS alone 7(17.1%)
WBRT alone 5(12.2%)
Table 4 Impact of patient characteristics and treatment
modality on the cause of death (n = 40)
Cause of death
Variables Neurological
(n = 23)
Systemic
(n = 17)
P-value
Lung metastasis 0.026
Yes 14 16
No 9 1
Extracranial metastasis 0.107
Yes 16 16
No 7 1
Brain hemorrhage 0.538
Yes 12 7
No 11 10
Number of BM 0.337
11 5 8
≥ 28 9
RPA class < 0.0001
Io rI I 8 1 6
III 15 1
Treatment for BM 0.024
Steroid only 17 6
Surgery or WBRT
and/or SRS
61 1
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the incidence of BM from HCC was 0.47%. However, as
has been stated by Choi et al. [7], these figures probably
underestimate the true frequency. In our institution, brain
scans are not routine for HCC patients. Almost all patients
included in this study were diagnosed on the basis of
symptoms. As a result, asymptomatic patients with BM
may have been missed.
The prognosis in HCC with BM is very poor. As
reported in most of the larger studies, overall survival
from the time of BM diagnosis is between 1 and 3.7
months [7,10,21]. Our survival result of 3 months con-
curs with these reports. However, some subsets of
patients may benefit from aggressive treatment. In some
case reports, survival extended to 12 months after com-
prehensive treatment [22]. Larger studies have reported
a survival time of more than 4 months in patients who
received surgery and/or radiotherapy [7,10,11]. The
median survival of patients who underwent resection
and WBRT can increase to almost 9 months [7]. On the
other hand, median survival in patients who received
supportive care only was less than 1 month [7,10]. In
our study, median survival was 4.5 months for patients
who underwent resection and/or radiotherapy, com-
pared to 1.5 months for those treated with supportive
care alone. However, not all patients with BM would
benefit from aggressive treatment. The identification of
prognostic factors would serve to guide the physician
into making optimal treatment decisions.
The RPA class has been proposed as an independent
prognostic factor for patients with BM from other pri-
mary tumors [23,24]. In a study by Choi et al. [7], 62
patients with HCC and BM were included, and patients
in RPA classes I and II demonstrated an improved sur-
vival when compared to those in RPA class III. How-
ever, this relationship was not found to be significant in
a further small report [11]. In our study, RPA class was
shown to be an independent prognostic factor in multi-
variate analysis. This result suggests that patients in
RPA class I and II may benefit from aggressive
treatment.
Patients with extracranial metastases at the time of
diagnosis of BM were usually considered to have a high
burden of tumor. In patients with BM from other pri-
mary tumors, the presence of extracranial metastases
has been shown to be associated with a poor prognosis
[23,25]. The impact of the presence of BM on survival
in patients with HCC remains unclear. In a study by
Chung et al. [11], the presence of extracranial metas-
tases was negatively associated with progression free
survival. However, this association was not statistically
Figure 1 Kaplan-Meier analyses of overall survival (OS) for 41
patients according to different prognostic factors (overall
comparison was performed by log-rank test).O S( a), OS based
on RPA (p < 0.0001) (b), presence of extracranial metastasis (p <
0.0001) (c).
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Patients Mean survival (months) Median survival (months) p-Value (log-rank)
Overall survival 41 4.5 3
Characteristics
Gender 0.386
Male 33 4.7 3
Female 8 3.6 2.5
Age (years)
< 50 23 4.4 3 0.893
≥ 50 18 4.6 3.5
Primary tumor 0.156
Controlled 16 5.8 3.5
Uncontrolled 25 3.7 3
Etiology
Hepatitis B 30 4.1 3 0.308
None 11 5.6 3
Child-Pugh’s classification
A 27 4.9 3.5 0.364
B/C 14 3.8 3
APF (ng/ml)
< 400 15 3.4 2 0.218
≥ 400 26 5.1 3.5
CEA (ng/ml)
< 5 26 4.8 3 0.725
≥ 5 5 3.9 3
CA199 (u/ml) 0.455
< 35 22 3.9 3
≥ 35 10 5.6 3
Extracranial metastasis
Yes 33 5.2 3.5 < 0.0001
No 8 1.4 1
Lung metastasis
Yes 31 5.4 4 0.001
No 10 1.7 1.7
Bone metastasis
Yes 9 5.8 4 0.272
No 32 4.1 2.5
Brain hemorrhage
Yes 19 4.1 1.5 0.495
No 22 4.9 3.5
Interval (months)
< 12 16 3.5 3 0.272
≥ 12 25 5.1 3.5
Number of brain lesions
Single 24 4.2 3 0.572
Multiple 17 4.9 3.5
Location
Supratentorial 29 5 3 0.293
Infratentorial or combinations 12 3.4 1.5
Treatment
Surgery or WBRT and/or SRS 18 6.8 4.5 0.001
Steroid only 23 2.7 1.5
RPA class
I or II 25 6.4 6 < 0.0001
III 16 1.6 1
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Page 6 of 9significant. A further study revealed a positive associa-
tion between median survival and the presence of extra-
cranial metastases [7], although statistical significance
was again not achieved. On the other hand, the presence
of extracranial metastases prior to a diagnosis of BM
was shown to be positively associated with survival in
our study. We also found that 87.5% of patients died
from progressive BM, whereas only 51.6% of patients
with extracranial metastases died from progressive BM.
In addition, it was found that patients who did not have
lung metastases were more likely to die of progressive
brain lesions, which may imply that patients with HCC
and BM first, may have tumors that are more poorly dif-
ferentiated and result in a more aggressive neurovascu-
lar invasion. Further studies are needed to elucidate the
impact of the presence of extracranial metastases on
survival in patients with BM from HCC.
Other important factors may impact on survival of
patients with HCC and BM. As the majority of those with
HCC have concurrent cirrhosis [3], the activity of the pri-
mary tumor and liver function will influence decisions on
treatment, and thereby survival. The Child-Pugh classifica-
tion is used to evaluate the status of liver function, and
s e r u mA F Pi st h em o s tu s e f u lt u m o rm a r k e rt or e f l e c t
tumor burden in HCC [3]. Both parameters have been
Table 6 Multivariate analysis of survival (n = 41)
Variable Hazard ratio 95.0% CI P value
Extracranial metastasis 0.015
Yes 0.337 0.14-0.81
No 1 ——
RPA class < 0.0001
I or II 0.169 0.07-0.41
III 1 ——
Treatment < 0.0001
Surgery or WBRT and/or SRS 0.28 0.14-0.57
Steroid only 1 ——
Figure 2 Kaplan-Meier analyses of overall survival (OS) for 41 patients according to different treatment modalities (overall comparison
was performed by log-rank test) (p = 0.001).
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[7]. A recent study demonstrated that a controlled primary
tumor was an independent prognostic factor for patients
with HCC and extra-hepatic metastases [20]. However, a
further retrospective report failed to confirm this associa-
tion [7]. Additionally, the number of brain lesions is also
an important prognostic factor. Many studies have shown
that a limited number of brain lesions is associated with a
relatively improved survival rate [26], and the median sur-
vival of patients with single brain lesions appears longer
than that observed in those with multiple lesions [7].
However, we failed to identify any of these parameters as
prognostic factors in the present study.
The cause of death for patients with BM from HCC has,
to date, been largely unknown. In the present study, the
majority of patients were followed up successfully. We
explored the relationship between patient characteristics
and the cause of death. The results showed that patients
in a low RPA class were more likely to die from systemic
disease, rather than from progression of BM. Additionally,
a properly aggressively treatment had a significant impact
on the cause of death, which again confirms its influence
on prognosis in patients with BM from HCC. A more rig-
orous determination of systemic versus neurological causes
of death could be clarified in a larger study.
Hepatitis B infection is the greatest risk factor for HCC
in most geographic areas, with the highest rates in China,
Taiwan and Korea [1]. Therefore, similar to previous
reports from Korea and Taiwan [7,10,11], the majority of
patients in this study had been infected with hepatitis B.
The interval between diagnosis of HCC and diagnosis of
BM varies in different reports, ranging from 2-54 months
[13]. The most recent large series from Korea and
Taiwan reported a median interval of 10.5-18.5 months
[7,10,11]. Our results were similar, with a median interval
between diagnosis of the primary disease and discovery of
brain lesions of 15 months. According to previous
reviews and reports [7,10,11,13], BM from HCC usually
occurs concurrently with a high rate of extracranial
metastases. This was confirmed in our study, where
80.5% of patients had concurrent extracranial metastasis.
In line with other reports, the lung was the most com-
mon site of extracranial metastases (75.6%), followed by
bone (22%) [7,10,11,13,18,19]. These results indicate that
BM from HCC is indicative of late stage disease, and the
presence of systemic metastases should be assessed in
HCC patients with BM.
The characteristics of brain lesions described in this
study were similar to other reports [7,10,11,13,21]. The
distribution of metastasis was supratentorial in 70.7% of
our patients compared with 54.8%-83.3% in previous
reports [7,10,11,21]. The occurrence of a single metastasis
was also similar to earlier studies: 58.5% vs. 50%-66.7%.
BM from HCC is frequently associated with hemorrhage
as has been reported on many occasions [7,10,11,13,21].
Similarly, 46.3% of patients in our study presented with
hemorrhagic brain metastases. Some experts [7] suggest
that the hypervascularity of HCC and the underlying coa-
gulopathy due to liver cirrhosis may explain this observa-
tion. Hsieh et al. [21] compared the clinical characteristics
of patients with and without intracranial hemorrhage, and
found that only habitual alcohol consumption was a signif-
icant predictor of intracranial hemorrhage in patients with
HCC and BM.
Conclusions
Limited patient samples and its retrospective nature
reduce the statistical power of this study. Nonetheless,
this first report from a large database in China confirms
the clinical characteristics and poor prognosis of
patients with HCC and BM. RPA class was identified as
an independent prognostic factor, and this association
can be applied for the determination of favorable and
unfavorable subgroups of patients and optimal treatment
strategies. The clinical implications of the presence of
extracranial metastases in patients with BM from HCC
need further assessment. Our results strongly indicate
that sufficiently aggressive treatment may improve prog-
nosis in favorable patient subgroups.
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